

DEFENCE THERAPEUTICS INC.

200 Burrard Street, Suite 1680
Vancouver, BC, V6C 3L6
Tel: 514.947.2272 Fax: 604.357.1704

**NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
TO BE HELD ON DECEMBER 9, 2021**

NOTICE IS HEREBY GIVEN that the 2021 annual general and special meeting (the “**Meeting**”) of the shareholders of Defence Therapeutics Inc. (the “**Company**”) will be held at 200 Burrard Street, Suite 1680, Vancouver, British Columbia, V6C 3L6, on Thursday, December 9, 2021, at 9:00 a.m. (Pacific time) for the following purposes:

1. To receive the audited financial statements of the Company for the year ended June 30, 2021, and the report of the auditor thereon.
2. To set the number of directors for the ensuing year at six.
3. To elect directors for the ensuing year.
4. To appoint the auditor of the Company for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditor.
5. To consider and if thought fit, pass a special resolution to approve the amendments to the Company’s Articles and Notice of Articles, as more particularly set out in the Company’s management information circular dated November 9, 2021, accompanying this Notice of Meeting (the “**Information Circular**”).
6. To transact such other business as may properly come before the Meeting or any adjournments thereof.

This Notice is accompanied by the Information Circular and either a form of proxy for registered shareholders or a voting instruction form for beneficial shareholders. Shareholders are requested to read the Information Circular and, if unable to attend the Meeting in person, complete, date, sign and return the proxy or voting instruction form, as applicable, so that as large a representation as possible may be had at the Meeting.

The Board of Directors of the Company has fixed the close of business on November 4, 2021, as the record date, being the date for the determination of the registered holders of common shares entitled to receive notice of, and to vote at, the Meeting and any adjournment thereof. The Board of Directors has also fixed 9:00 a.m. (Pacific time) on December 7, 2021, or no later than 48 hours before the time of any adjourned Meeting (excluding Saturdays, Sundays and holidays), as the time before which proxies to be used or acted upon at the Meeting or any adjournment thereof shall be deposited with the Company’s registrar and transfer agent, Computershare Trust Company.

Due to the COVID-19 pandemic and given the restrictions on public gatherings and in the best interest of the health of all participants in the Meeting, the Company respectfully asks that shareholders do not attend the Meeting in person. The Company requests that shareholders who wish to participate by listening to the Meeting, contact the Company by 9:00 am Pacific time on December 7, 2021, at ccesarone@defencetherapeutics.com to be included in the teleconference for the Meeting. The Company will arrange for teleconference participation for all shareholders who have requested it by 9:00 am Pacific time on December 7, 2021. The Company strongly recommends that shareholders vote by Proxy or by a request for voting instructions well in advance of the Meeting. If public health guidelines regarding physical distancing in British Columbia have changed by the Meeting date of December 9, 2021, the Company may issue a news release advising of permitted Meeting attendance in accordance with such updated guidelines.

DATED at Vancouver, British Columbia, as of the 9th of November, 2021.

DEFENCE THERAPEUTICS INC.

By: “*Sébastien Plouffe*”
Chief Executive Officer